SCHEMBL19366298

SCHEMBL19366298

CCC1CCc2cc(OCn3ccnc3)ccc2C1C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDM4E B2RXH2 4/20 0.36
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35
HTT P42858 1/20 0.35
POLB P06746 1/20 0.35
CYP19A1 P11511 3/20 0.35
LMNA P02545 2/20 0.34
ATM Q13315 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17531514 0.85 KMT2A (0.36) ALDH1A1NPSR1KDM4EKMT2AMEN1
SCHEMBL19366289 0.79 HSD17B2 (0.36) CYP19A1
SCHEMBL19366472 0.79 HRH3 (0.45) CYP19A1
SCHEMBL17538358 0.78 HTT (0.39) ALDH1A1NPSR1KDM4EKMT2AMEN1
SCHEMBL19366374 0.76 CYP1A1 (0.51)
SCHEMBL19366288 0.75 HRH3 (0.47) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL19067871 0.69 CYP1B1 (0.37)
SCHEMBL19067961 0.69 ESR1 (0.47) KMT2AMEN1CYP19A1CYP2D6
SCHEMBL19366291 0.67 MEN1 (0.33) ALDH1A1NPSR1KDM4EKMT2AMEN1
SCHEMBL11188675 0.67 ALDH1A1 (0.60) ALDH1A1NPSR1KDM4EKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-04-14 US disclosed
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity AR, NR5A1, BRCA1 ALDH1A1 2392/4885NPSR1 400/4885KDM4E 1575/4885
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY AR, NR5A1, BRCA1 ALDH1A1 2392/4885NPSR1 400/4885KDM4E 1575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.